RESUMEN
OBJECTIVE: Dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) has previously shown alterations in cerebral perfusion in patients with systemic lupus erythematosus (SLE). However, the results have been inconsistent, in particular regarding neuropsychiatric (NP) SLE. Thus, we investigated perfusion-based measures in different brain regions in SLE patients with and without NP involvement, and additionally, in white matter hyperintensities (WMHs), the most common MRI pathology in SLE patients. MATERIALS AND METHODS: We included 3 T MRI images (conventional and DSC) from 64 female SLE patients and 19 healthy controls (HC). Three different NPSLE attribution models were used: the Systemic Lupus International Collaborating Clinics (SLICC) A model (13 patients), the SLICC B model (19 patients), and the American College of Rheumatology (ACR) case definitions for NPSLE (38 patients). Normalized cerebral blood flow (CBF), cerebral blood volume (CBV) and mean transit time (MTT) were calculated in 26 manually drawn regions of interest and compared between SLE patients and HC, and between NPSLE and non-NPSLE patients. Additionally, normalized CBF, CBV and MTT, as well as absolute values of the blood-brain barrier leakage parameter (K2) were investigated in WMHs compared to normal appearing white matter (NAWM) in the SLE patients. RESULTS: After correction for multiple comparisons, the most prevalent finding was a bilateral significant decrease in MTT in SLE patients compared to HC in the hypothalamus, putamen, right posterior thalamus and right anterior insula. Significant decreases in SLE compared to HC were also found for CBF in the pons, and for CBV in the bilateral putamen and posterior thalamus. Significant increases were found for CBF in the posterior corpus callosum and for CBV in the anterior corpus callosum. Similar patterns were found for both NPSLE and non-NPSLE patients for all attributional models compared to HC. However, no significant perfusion differences were revealed between NPSLE and non-NPSLE patients regardless of attribution model. The WMHs in SLE patients showed a significant increase in all perfusion-based metrics (CBF, CBV, MTT and K2) compared to NAWM. CONCLUSION: Our study revealed perfusion differences in several brain regions in SLE patients compared to HC, independently of NP involvement. Furthermore, increased K2 in WMHs compared to NAWM may indicate blood-brain barrier dysfunction in SLE patients. We conclude that our results show a robust cerebral perfusion, independent from the different NP attribution models, and provide insight into potential BBB dysfunction and altered vascular properties of WMHs in female SLE patients. Despite SLE being most prevalent in females, a generalization of our conclusions should be avoided, and future studies including all sexes are needed.
Asunto(s)
Lupus Eritematoso Sistémico , Vasculitis por Lupus del Sistema Nervioso Central , Humanos , Femenino , Barrera Hematoencefálica/diagnóstico por imagen , Lupus Eritematoso Sistémico/diagnóstico por imagen , Lupus Eritematoso Sistémico/patología , Angiografía por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/métodos , Vasculitis por Lupus del Sistema Nervioso Central/patología , PerfusiónRESUMEN
AIM: Inhibition of diacylglycerol acyltransferase 1 (DGAT1) is a potential treatment modality for patients with type 2 diabetes mellitus and obesity, based on preclinical data suggesting it is associated with insulin sensitization and weight loss. This randomized, placebo-controlled, phase 1 study in 62 overweight or obese men explored the effects and tolerability of AZD7687, a reversible and selective DGAT1 inhibitor. METHODS: Multiple doses of AZD7687 (1, 2.5, 5, 10 and 20 mg/day, n = 6 or n = 12 for each) or placebo (n = 20) were administered for 1 week. Postprandial serum triacylglycerol (TAG) was measured for 8 h after a standardized 45% fat meal. Glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) were measured and a paracetamol challenge was performed to assess gastric emptying. RESULTS: Dose-dependent reductions in postprandial serum TAG were demonstrated with AZD7687 doses ≥5 mg compared with placebo (p < 0.01). Significant (p < 0.001) increases in plasma GLP-1 and PYY levels were seen at these doses, but no clear effect on gastric emptying was demonstrated at the end of treatment. With AZD7687 doses >5 mg/day, gastrointestinal (GI) side effects increased; 11/18 of these participants discontinued treatment owing to diarrhoea. CONCLUSIONS: Altered lipid handling and hormone secretion in the gut were demonstrated during 1-week treatment with the DGAT1 inhibitor AZD7687. However, the apparent lack of therapeutic window owing to GI side effects of AZD7687, particularly diarrhoea, makes the utility of DGAT1 inhibition as a novel treatment for diabetes and obesity questionable.
Asunto(s)
Acetatos/uso terapéutico , Fármacos Antiobesidad/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diacilglicerol O-Acetiltransferasa/antagonistas & inhibidores , Diarrea/inducido químicamente , Obesidad/tratamiento farmacológico , Pirazinas/uso terapéutico , Acetatos/efectos adversos , Adulto , Fármacos Antiobesidad/efectos adversos , Diacilglicerol O-Acetiltransferasa/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Vaciamiento Gástrico/efectos de los fármacos , Péptido 1 Similar al Glucagón/efectos de los fármacos , Humanos , Absorción Intestinal/efectos de los fármacos , Masculino , Persona de Mediana Edad , Péptido YY/efectos de los fármacos , Pirazinas/efectos adversos , Resultado del Tratamiento , Pérdida de Peso/efectos de los fármacosRESUMEN
AIMS: Inhibition of diacylglycerol acyltransferase 1 (DGAT1), which catalyses the final step in triacylglycerol (TAG) assembly, is suggested as a treatment for type 2 diabetes and obesity based on animal data indicating insulin sensitization and weight reduction. This first-time-in-human single ascending dose study explored the safety, tolerability, pharmacokinetics and pharmacodynamics of the selective DGAT1 inhibitor AZD7687. METHODS: Eighty healthy male subjects were enrolled. In each of 10 cohorts, six subjects received the same dose of AZD7687 orally (range across cohorts 1-60 mg) and two placebo. Plasma AZD7687 exposure was measured repeatedly. Postprandial serum TAG excursion was measured during 8 h after a standardized mixed meal with fat energy content of 60% (SMM 60%; five cohorts, 1-20 mg), before (baseline) and after dosing, to assess effects on gut DGAT1 activity. RESULTS: AZD7687 markedly reduced postprandial TAG excursion with a steep concentration-effect relationship. Incremental TAG AUC (area under the serum concentration vs. time curve) following SMM 60% was decreased >75% from baseline at doses ≥5 mg (p < 0.0001 vs. placebo). Serum levels of diacylglycerol, specifically measured with mass spectrometry, did not increase after AZD7687 administration. Nausea, vomiting and diarrhoea were reported with increasing doses and they limited dose escalation. Lowering of SMM fat content to 45 or 30% in five cohorts gradually reduced the frequency of gastrointestinal symptoms at a given dose of AZD7687. CONCLUSIONS: The attenuating effect of AZD7687 on postprandial TAG excursion provides proof of mechanism with respect to gut DGAT1 inhibition. However, dose and diet-related gastrointestinal side effects may impact further development of DGAT1 inhibitors.
Asunto(s)
Acetatos/farmacología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diacilglicerol O-Acetiltransferasa/antagonistas & inhibidores , Resistencia a la Insulina , Absorción Intestinal/efectos de los fármacos , Pirazinas/farmacología , Triglicéridos/metabolismo , Acetatos/administración & dosificación , Adulto , Área Bajo la Curva , Estudios de Cohortes , Diabetes Mellitus Tipo 2/sangre , Diglicéridos/sangre , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Espectrometría de Masas , Periodo Posprandial , Pirazinas/administración & dosificación , Resultado del TratamientoRESUMEN
AIMS: To assess the safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus (T2DM). METHODS: This randomized, single-blind, placebo-controlled, monotherapy study was carried out in two parts. In part A, 32 patients received AZD1656 (7, 20, 40 or 80 mg) twice daily or placebo for 8 days in hospital. In part B, another 20 patients received, as outpatients, individually titrated AZD1656 15-45 mg twice daily or placebo for 28 days. Safety, pharmacokinetics and pharmacodynamic variables were evaluated. RESULTS: AZD1656 was generally well tolerated. Pharmacokinetics of AZD1656 were virtually dose- and time-independent. AZD1656 was rapidly absorbed and eliminated. An active metabolite was formed which had a longer half-life than AZD1656, but showed â¼15% of the area under the plasma concentration versus time curve from 0 to 24 h compared with that of AZD1656. Renal excretion of AZD1656 and the metabolite was low. In part A, fasting plasma glucose (FPG) was reduced by up to 21% and mean 24-h plasma glucose was reduced by up to 24% with AZD1656 versus placebo, depending on dose. No dose-related changes in serum insulin or C-peptide were observed with AZD1656 at the end of treatment. Results in part B confirmed the glucose-lowering effect of AZD1656 versus placebo. CONCLUSIONS: AZD1656 was well tolerated with predictable pharmacokinetics in patients with T2DM. Dose-dependent reductions in plasma glucose were observed.
Asunto(s)
Azetidinas/farmacología , Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Glucoquinasa/efectos de los fármacos , Hemoglobina Glucada/efectos de los fármacos , Hipoglucemiantes/farmacología , Pirazinas/farmacología , Adulto , Azetidinas/administración & dosificación , Azetidinas/efectos adversos , Azetidinas/farmacocinética , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/sangre , Relación Dosis-Respuesta a Droga , Femenino , Polipéptido Inhibidor Gástrico/efectos de los fármacos , Péptido 1 Similar al Glucagón/efectos de los fármacos , Glucoquinasa/metabolismo , Hemoglobina Glucada/metabolismo , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/farmacocinética , Incretinas/metabolismo , Insulina/metabolismo , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/efectos de los fármacos , Pirazinas/administración & dosificación , Pirazinas/efectos adversos , Pirazinas/farmacocinética , Método Simple Ciego , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVES: Gastro-oesophageal reflux disease (GORD) is a common gastrointestinal disorder with a genetic component. Our aim was to identify genetic factors associated with GORD. PATIENTS AND METHODS: Four separate patient cohorts were analysed using a step-wise approach. (1) Whole genome linkage analysis was performed in 36 families. (2) Candidate genes were tested for GORD association in a trio cohort. (3) Genetic association was replicated in a case-control cohort. We also investigated genetic association to hiatus hernia (HH). (4) Protein expression was analysed in oesophageal biopsies. RESULTS: A region on chromosome 2, containing collagen type III alpha 1 (COL3A1), was identified (LOD = 3.3) in families with dominant transmission of GORD, stratified for hiatus hernia (HH). COL3A1 showed significant association with GORD in an independent paediatric trio cohort (p(corr) = 0.003). The association was male specific (p(corr) = 0.018). The COL3A1 association was replicated in an independent adult case control cohort (p(corr) = 0.022). Moreover, male specific association to HH (p(corr) = 0.019) was found for a SNP not associated to GORD. Collagen type III protein was more abundant in oesophageal biopsies from male patients with GORD (p = 0.03). CONCLUSION: COL3A1 is a disease-associated gene in both paediatric and adult GORD. Furthermore, we show that COL3A1 is genetically associated with HH in adult males. The GORD- and HH-associated alleles are different, indicating two separate mechanisms leading to disease. Our data provides new insight into GORD aetiology, identifying a connective tissue component and indicating a tissue remodelling mechanism in GORD. Our results implicate gender differences in the genetic risk for both for GORD and HH.
Asunto(s)
Colágeno Tipo III/genética , Reflujo Gastroesofágico/genética , Hernia Hiatal/genética , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Mapeo Cromosómico , Colágeno Tipo III/metabolismo , Análisis Mutacional de ADN , Esófago/metabolismo , Femenino , Reflujo Gastroesofágico/complicaciones , Reflujo Gastroesofágico/metabolismo , Predisposición Genética a la Enfermedad , Genotipo , Hernia Hiatal/etiología , Humanos , Lactante , Masculino , Polimorfismo de Nucleótido Simple , Factores de Riesgo , Factores SexualesRESUMEN
The aim of the present study was to assess the inotropic effects of vasoactive intestinal peptide (VIP) on isolated myocardial trabeculae from the right atrium and the left ventricle of human hearts. Furthermore, using reverse transcriptase-PCR, we wanted to determine the presence of mRNAs encoding the three cloned human VIP receptors, VPAC(1), VPAC(2) and PAC(1). The trabeculae were paced at 1.0 Hz in tissue baths, and changes in isometric contractile force upon exposure to agonist were studied. VIP had a potent positive inotropic effect in some of the atrial and ventricular trabeculae tested. This effect was almost completely blocked by the VIP-receptor antagonist VIP-(6-28). mRNAs encoding the human VPAC(1), VPAC(2) and PAC(1) receptors were detected in human myocardial trabeculae from both the right atrium and the left ventricle. In conclusion, VIP has a direct positive inotropic effect in both the atria and the ventricles of the human heart. The presence of mRNAs for the VPAC(1), VPAC(2) and PAC(1) receptors suggest that VIP may mediate its effect via these receptors.
Asunto(s)
Cardiotónicos/farmacología , Corazón/efectos de los fármacos , Péptido Intestinal Vasoactivo/farmacología , Adolescente , Adulto , Relación Dosis-Respuesta a Droga , Electroforesis en Gel de Agar , Femenino , Humanos , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Contracción Miocárdica/efectos de los fármacos , Fragmentos de Péptidos/farmacología , ARN Mensajero/genética , Receptores de Péptido Intestinal Vasoactivo/antagonistas & inhibidores , Receptores de Péptido Intestinal Vasoactivo/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Until 1991, the Russian city of Samara was largely isolated from other parts of Russia and the rest of the world. Very recently, Samara has seen an alarming increase in the incidence of hepatitis. The proportion of fulminant cases is unusually high. We wanted to assess the roles of hepatitis B virus (HBV) and hepatitis D virus (HDV) in acute viral hepatitis in this region by analyzing the prevailing strains of both and by determining their genotypes and possible origin. Serum samples were screened for different serological markers and by PCR followed by direct sequencing. Of the 94 HBV-positive samples (80% of which were acute infections), 37 (39%) were also HDV positive. Sixty-seven percent of the patients had anti-HCV antibodies. Twenty-five percent of all patients in the study had fulminant hepatitis. Statistically significant sex differences were found among fulminant cases. For HBV, the core promoter sequences of 62 strains were determined and all but one were found to be of genotype D. None of these had any deletions. Only one strain, from a patient with fulminant fatal hepatitis, showed multiple mutations. The pre-S2 region sequences of 31 HBV strains were also compared. Phylogenetically, these fell into two distinct groups within genotype D, suggesting different origins. For HDV, part of the region encoding the delta-antigen was sequenced from four strains. All proved to be of genotype I and were similar to Far Eastern and Eastern European strains. The contribution of intravenous drug use to the sharp increase in viral hepatitis in this unique setting is discussed.
Asunto(s)
Virus de la Hepatitis B/genética , Hepatitis B/epidemiología , Hepatitis D/epidemiología , Virus de la Hepatitis Delta/genética , Enfermedad Aguda , Adolescente , Adulto , Anciano , ADN Viral/análisis , Femenino , Hepacivirus/genética , Hepatitis B/diagnóstico , Hepatitis C/diagnóstico , Hepatitis C/epidemiología , Hepatitis D/diagnóstico , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Filogenia , Federación de Rusia/epidemiología , Análisis de Secuencia de ADNRESUMEN
Horizontal transmission of hepatitis B virus (HBV) without apparent sexual or parenteral exposure is common in hyperendemic areas. In most cases, the route of transmission is unknown. To investigate urine as a potential source of infection, serum and urine from 56 chronic hepatitis B surface antigen (HBsAg) carriers were examined for the presence of HBV DNA using the polymerase chain reaction (PCR). Thirty-four of the patients were anti-hepatitis B e antigen (anti-HBe) positive and 22 were hepatitis B e antigen (HBeAg) positive. HBV DNA was detected in serum from 46 patients (82%) and in urine from 28 patients (50%). Most HBeAg-positive patients had HBV DNA detectable in urine (91%), whereas urine samples from anti-HBe-positive patients were found to contain HBV DNA to a lesser extent (24%). When comparing HBV DNA from serum and urine by an end-point titration PCR, a titration difference averaging 10(3) was found between serum and urine. A significant female predominance was also noted among the positive urine samples (P < 0.05), which was not correlated to the presence of haematuria. Detection of HBV DNA may indicate active viral replication, and thereby infectivity. Because a high proportion of chronic HBV carriers were found to have HBV DNA in urine, it is suggested that irrespective of HBeAg/anti-HBe status, urine should be regarded as a potential route of transmission and therefore be investigated further as a means of horizontal and nosocomial transmission of HBV.
Asunto(s)
Portador Sano/virología , ADN Viral/orina , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/virología , Orina/virología , Adulto , Sangre/virología , Portador Sano/transmisión , ADN Viral/sangre , Femenino , Hepatitis B/transmisión , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos e de la Hepatitis B/sangre , Antígenos e de la Hepatitis B/inmunología , Virus de la Hepatitis B/fisiología , Humanos , Masculino , Reacción en Cadena de la Polimerasa/métodos , Replicación ViralRESUMEN
The use of a novel chiral functional monomer system in molecular imprinting protocols is described. The monomer, dibenzyl (2R,3R)-O-monoacryloyl tartrate, possesses a hydroxyl moiety which can be used to direct template-functional monomer interactions during molecular imprinting polymerization. This system simultaneously positions benzyl ester-protected carboxyl groups in close proximity to the template, which upon deprotection yield recognition sites with stronger ligand-binding capacities. Furthermore, the inherent chirality of the monomer engenders the polymer with an inbuilt preference for a given stereoisomer. Application of the system to the molecular imprinting of the cinchonidine alkaloids (+)-cinchonine and (-)-cinchonidine yielded stereoselective polymers. The effect of imprinting (+)-cinchonine produced a polymer which more than reversed the inherent chiral selectivity of the chiral monomer residues present in the matrix.
Asunto(s)
Imitación Molecular , Polímeros/síntesis química , Sitios de Unión , Alcaloides de Cinchona/síntesis química , Alcaloides de Cinchona/química , Ligandos , Polímeros/química , EstereoisomerismoRESUMEN
The potential of on-line combination of supported liquid membrane extraction and column liquid chromatography with a phenol oxidase-based biosensor as a selective detection unit has been investigated for the determination of phenols in human plasma. The phenols are selectively extracted into a porous PTFE (polytetraflouroethene) membrane impregnated with a water-immiscible organic solvent and further into an alkaline acceptor phase. Via an ion-exchange interface, the analytes are transferred to a reversed-phase column where they are separated and detected using the biosensor. No sample pretreatment before the extraction, except centrifugation, is made. Due to the high selectivity both in the extraction and in the detection steps and to the fact that the demands on the chromatographic separation are low, a quick separation using an eluent with a low concentration of organic modifier can be made, without affecting the biosensor response. Detection limits below the 50 microg/l level in blood plasma were obtained for the three model compounds, phenol, p-cresol and 4-chlorophenol.
Asunto(s)
Técnicas Biosensibles , Fenoles/sangre , Clorofenoles/sangre , Cromatografía por Intercambio Iónico , Cromatografía Liquida , Cresoles/sangre , Humanos , Concentración de Iones de Hidrógeno , Membranas , Monofenol Monooxigenasa , Fenol/sangre , Sensibilidad y EspecificidadRESUMEN
The effect of modern low-dose oral contraceptives (OCs) on the levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in young, health, nulligravid women was studied in two independent samples. Elevated FSH levels were seen in former OC users compared with never users regardless of menstrual cycle phase. The increase in FSH levels seemed to peak one year after cessation of OC use. This relationship was still significant after exclusion of women with low progesterone levels. LH levels were significantly higher in former users compared with never users in the first sample, but not in the second sample. The difference in FSH concentrations was very small. Single blood samples were obtained from the subjects at each time point even though it is recognized that gonadotropin secretion is pulsatile. These results must be regarded as preliminary and unconfirmed due to small sample size.
PIP: At the University Hospital in Lund, Sweden, researchers grouped healthy nulliparous women aged 19-25 into current, former, and never users of low-dose combined oral contraceptives (OCs) to examine the effect of the OCs on the levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH). The subjects were from two independent samples. Based on the day the blood was sampled, their hormone level readings were divided into follicular and luteal phases. Former OC users had higher FSH levels than did never users, regardless of menstrual cycle phase (group 1: 1.9 vs. 1.6 mcg/l for follicular phase, 1.6 vs. 1 mcg/l for luteal phase; p = 0.004) (group 2: 2.05 vs. 1.7 mcg/l, 1.55 vs. 1.25 mcg/l; p = 0.028). The transient increase of FSH levels appeared to peak 12 months after the women stopped using the OC. The researchers found that the temporary increase in FSH levels was still significant after they excluded eight women with low progesterone levels (10 nmol/l in luteal phase and 3.5 nmol/l in follicular phase) and adjusted for age (p = 0.015). LH levels were much higher in former users than never users in the first sample (1.6 vs. 1 mcg/l for follicular phase, 1.8 vs. 1.15 mcg/l for luteal phase; p = 0.014), but not in the second sample. Smoking and time since awakening had no effect on FSH and LH levels. Present users experienced suppressed FSH and LH levels. These findings indicate that former OC users experience a rebound-like phenomenon in FSH levels. Since the sample size was small and only one blood sample was taken from each woman at each of the sampling times, the researchers caution that these findings are preliminary and unconfirmed.
Asunto(s)
Anticonceptivos Orales/farmacología , Hormona Folículo Estimulante/sangre , Adulto , Envejecimiento/sangre , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hormona Luteinizante/sangre , Ciclo Menstrual/fisiología , Progesterona/sangre , Progestinas/farmacología , Radioinmunoensayo , Fumar/sangre , Factores de TiempoRESUMEN
The study was designed to investigate if modern low dosage combined oral contraceptives were associated with changes in plasma prolactin levels in healthy nulliparous women aged 19-25. Plasma prolactin was not significantly correlated to oral contraceptive use, nor to smoking habits. Plasma prolactin was, however, significantly negatively correlated to time since awakening. A significant two-way interaction on prolactin was also seen between smoking and present oral contraceptive use. In our material the mean values of plasma prolactin were higher in the follicular phase than in the luteal phase, although not significantly.